Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic
Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company51 percent of Medsenic shares (valued at ca EUR 40 million) to...
Source: pharmiweb.com